Literature DB >> 34183003

Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19.

Carlota Dobaño1, Anna Ramírez-Morros2, Gemma Moncunill3, Anna Ruiz-Comellas4,5,6, Selena Alonso3, Josep Vidal-Alaball4,5, Gemma Ruiz-Olalla3, Marta Vidal3, Rocío Rubio3, Emma Cascant3, Daniel Parras7, Natalia Rodrigo Melero8, Pau Serra7, Carlo Carolis8, Pere Santamaria7,9, Anna Forcada10, Jacobo Mendioroz5,11, Ruth Aguilar3.   

Abstract

We assessed the duration and baseline determinants of antibody responses to SARS-CoV-2 spike antigens and the occurrence of reinfections in a prospective cohort of 173 Spanish primary health care worker patients followed initially for 9 months and subsequently up to 12.5 months after COVID-19 symptoms onset. Seropositivity to SARS-CoV-2 spike and receptor-binding domain antigens up to 149-270 days was 92.49% (90.17% IgG, 76.3% IgA, 60.69% IgM). In a subset of 64 health care workers who had not yet been vaccinated by April 2021, seropositivity was 96.88% (95.31% IgG, 82.81% IgA) up to 322-379 days post symptoms onset. Four suspected reinfections were detected by passive case detection, two among seronegative individuals (5 and 7 months after the first episode), and one low antibody responder. Antibody levels significantly correlated with fever, hospitalization, anosmia/hypogeusia, allergies, smoking, and occupation. Stable sustainment of IgG responses raises hope for long-lasting COVID-19 vaccine immunity.

Entities:  

Keywords:  Antibodies; Baseline determinants; COVID-19; Cohort; Duration; Health care workers; Kinetics; Reinfection; SARS-CoV-2; Spike antigen

Year:  2021        PMID: 34183003     DOI: 10.1186/s12916-021-02032-2

Source DB:  PubMed          Journal:  BMC Med        ISSN: 1741-7015            Impact factor:   8.775


  8 in total

1.  Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients.

Authors:  Chuanmiao Liu; Xiaoqi Yu; Chunming Gao; Li Zhang; Hui Zhai; Yanan Hu; Enhui Liu; Qiong Wang; Yu Gao; Dong Wei; Donghua Zhang; Yue Han; Xinxin Zhang
Journal:  J Med Virol       Date:  2020-11-10       Impact factor: 2.327

Review 2.  SARS-CoV-2 vaccines in development.

Authors:  Florian Krammer
Journal:  Nature       Date:  2020-09-23       Impact factor: 49.962

3.  Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.

Authors:  Zhenyu He; Lili Ren; Juntao Yang; Li Guo; Luzhao Feng; Chao Ma; Xia Wang; Zhiwei Leng; Xunliang Tong; Wang Zhou; Geng Wang; Ting Zhang; Yan Guo; Chao Wu; Qing Wang; Manqing Liu; Conghui Wang; Mengmeng Jia; Xuejiao Hu; Ying Wang; Xingxing Zhang; Rong Hu; Jingchuan Zhong; Jin Yang; Juan Dai; Lan Chen; Xiaoqi Zhou; Jianwei Wang; Weizhong Yang; Chen Wang
Journal:  Lancet       Date:  2021-03-20       Impact factor: 79.321

4.  Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production.

Authors:  Yuezhou Chen; Adam Zuiani; Stephanie Fischinger; Jyotsna Mullur; Caroline Atyeo; Meghan Travers; Felipe J N Lelis; Krista M Pullen; Hannah Martin; Pei Tong; Avneesh Gautam; Shaghayegh Habibi; Jillian Bensko; Deborah Gakpo; Jared Feldman; Blake M Hauser; Timothy M Caradonna; Yongfei Cai; John S Burke; Junrui Lin; James A Lederer; Evan Christopher Lam; Christy L Lavine; Michael S Seaman; Bing Chen; Aaron G Schmidt; Alejandro Benjamin Balazs; Douglas A Lauffenburger; Galit Alter; Duane R Wesemann
Journal:  Cell       Date:  2020-11-03       Impact factor: 41.582

5.  Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study.

Authors:  Jee Myung Yang; Hyun Yong Koh; Sung Yong Moon; In Kyung Yoo; Eun Kyo Ha; Seulgi You; So Young Kim; Dong Keon Yon; Seung Won Lee
Journal:  J Allergy Clin Immunol       Date:  2020-08-15       Impact factor: 10.793

6.  SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up.

Authors:  Gemma Moncunill; Alfredo Mayor; Rebeca Santano; Alfons Jiménez; Marta Vidal; Marta Tortajada; Sergi Sanz; Susana Méndez; Anna Llupià; Ruth Aguilar; Selena Alonso; Diana Barrios; Carlo Carolis; Pau Cisteró; Eugenia Chóliz; Angeline Cruz; Silvia Fochs; Chenjerai Jairoce; Jochen Hecht; Montserrat Lamoglia; Mikel J Martínez; Javier Moreno; Robert A Mitchell; Natalia Ortega; Nuria Pey; Laura Puyol; Marta Ribes; Neus Rosell; Antía Figueroa-Romero; Patricia Sotomayor; Sara Torres; Sarah Williams; Sonia Barroso; Anna Vilella; Antoni Trilla; Pilar Varela; Carlota Dobaño; Alberto L Garcia-Basteiro
Journal:  J Infect Dis       Date:  2021-01-04       Impact factor: 5.226

7.  Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection.

Authors:  Pyoeng Gyun Choe; Kye-Hyung Kim; Chang Kyung Kang; Hyeon Jeong Suh; EunKyo Kang; Sun Young Lee; Nam Joong Kim; Jongyoun Yi; Wan Beom Park; Myoung-Don Oh
Journal:  Emerg Infect Dis       Date:  2020-12-22       Impact factor: 16.126

8.  Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.

Authors:  Jeffrey Seow; Carl Graham; Blair Merrick; Sam Acors; Suzanne Pickering; Kathryn J A Steel; Oliver Hemmings; Aoife O'Byrne; Neophytos Kouphou; Rui Pedro Galao; Gilberto Betancor; Harry D Wilson; Adrian W Signell; Helena Winstone; Claire Kerridge; Isabella Huettner; Jose M Jimenez-Guardeño; Maria Jose Lista; Nigel Temperton; Luke B Snell; Karen Bisnauthsing; Amelia Moore; Adrian Green; Lauren Martinez; Brielle Stokes; Johanna Honey; Alba Izquierdo-Barras; Gill Arbane; Amita Patel; Mark Kia Ik Tan; Lorcan O'Connell; Geraldine O'Hara; Eithne MacMahon; Sam Douthwaite; Gaia Nebbia; Rahul Batra; Rocio Martinez-Nunez; Manu Shankar-Hari; Jonathan D Edgeworth; Stuart J D Neil; Michael H Malim; Katie J Doores
Journal:  Nat Microbiol       Date:  2020-10-26       Impact factor: 17.745

  8 in total
  15 in total

1.  Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek Patients.

Authors:  Stavroula Labropoulou; Niki Vassilaki; Raphaela S Milona; Evangelos Terpos; Marianna Politou; Vasiliki Pappa; Maria Pagoni; Elisavet Grouzi; Meletios A Dimopoulos; Andreas Mentis; Mary Emmanouil; Emmanouil Angelakis
Journal:  Viruses       Date:  2022-04-05       Impact factor: 5.818

2.  Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?

Authors:  Leimapokpam Sumitra Devi; Moumita Sardar; Mukesh Sharma; Manisha Khandait
Journal:  Int J Microbiol       Date:  2022-05-31

3.  Antibody conversion rates to SARS-CoV-2 in saliva from children attending summer schools in Barcelona, Spain.

Authors:  Carlota Dobaño; Selena Alonso; Gemma Moncunill; Iolanda Jordan; Mariona Fernández de Sevilla; Marta Vidal; Alfons Jiménez; Gemma Pons Tomas; Chenjerai Jairoce; María Melé Casas; Rocío Rubio; María Hernández García; Gemma Ruiz-Olalla; Mònica Girona-Alarcón; Diana Barrios; Rebeca Santano; Robert A Mitchell; Laura Puyol; Leonie Mayer; Jordi Chi; Natalia Rodrigo Melero; Carlo Carolis; Aleix Garcia-Miquel; Elisenda Bonet-Carne; Joana Claverol; Marta Cubells; Claudia Fortuny; Victoria Fumadó; Cristina Jou; Carmen Muñoz-Almagro; Luis Izquierdo; Quique Bassat; Eduard Gratacós; Ruth Aguilar; Juan José García-García
Journal:  BMC Med       Date:  2021-11-23       Impact factor: 8.775

4.  Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses.

Authors:  Emelie Marklund; Susannah Leach; Kristina Nyström; Anna Lundgren; Jan-Åke Liljeqvist; Staffan Nilsson; Aylin Yilmaz; Lars-Magnus Andersson; Mats Bemark; Magnus Gisslén
Journal:  Front Immunol       Date:  2021-11-02       Impact factor: 7.561

5.  COVID-19 in children and young adults with kidney disease: risk factors, clinical features and serological response.

Authors:  Jenny Weinbrand-Goichberg; Efrat Ben Shalom; Choni Rinat; Sapir Choshen; Shimrit Tzvi-Behr; Yaacov Frishberg; Rachel Becker-Cohen
Journal:  J Nephrol       Date:  2021-10-15       Impact factor: 4.393

6.  Ambient Air Pollution in Relation to SARS-CoV-2 Infection, Antibody Response, and COVID-19 Disease: A Cohort Study in Catalonia, Spain (COVICAT Study).

Authors:  Manolis Kogevinas; Gemma Castaño-Vinyals; Marianna Karachaliou; Ana Espinosa; Rafael de Cid; Judith Garcia-Aymerich; Anna Carreras; Beatriz Cortés; Vanessa Pleguezuelos; Alfons Jiménez; Marta Vidal; Cristina O'Callaghan-Gordo; Marta Cirach; Rebeca Santano; Diana Barrios; Laura Puyol; Rocío Rubio; Luis Izquierdo; Mark Nieuwenhuijsen; Payam Dadvand; Ruth Aguilar; Gemma Moncunill; Carlota Dobaño; Cathryn Tonne
Journal:  Environ Health Perspect       Date:  2021-11-17       Impact factor: 9.031

7.  Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination.

Authors:  Raquel Guiomar; Ana João Santos; Aryse Martins Melo; Inês Costa; Rita Matos; Ana Paula Rodrigues; Irina Kislaya; Anabela Santos Silva; Carla Roque; Carla Nunes; Joaquim Aguiar; Fátima Graça; Antônio Silva Graça; Ausenda Machado
Journal:  Vaccines (Basel)       Date:  2022-01-20

8.  SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia.

Authors:  Marianna Karachaliou; Gemma Moncunill; Manolis Kogevinas; Carlota Dobaño; Ana Espinosa; Gemma Castaño-Vinyals; Rocío Rubio; Marta Vidal; Alfons Jiménez; Esther Prados; Anna Carreras; Beatriz Cortés; Natàlia Blay; Marc Bañuls; Vanessa Pleguezuelos; Natalia Rodrigo Melero; Pau Serra; Daniel Parras; Luis Izquierdo; Pere Santamaría; Carlo Carolis; Kyriaki Papantoniou; Ximena Goldberg; Ruth Aguilar; Judith Garcia-Aymerich; Rafael de Cid
Journal:  BMC Med       Date:  2022-09-16       Impact factor: 11.150

9.  Comprehensive Flow Cytometry Profiling of the Immune System in COVID-19 Convalescent Individuals.

Authors:  Sergio Gil-Manso; Iria Miguens Blanco; Rocío López-Esteban; Diego Carbonell; Luis Andrés López-Fernández; Lori West; Rafael Correa-Rocha; Marjorie Pion
Journal:  Front Immunol       Date:  2022-01-06       Impact factor: 7.561

10.  Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection.

Authors:  Jan Van Elslande; Matthijs Oyaert; Natalie Lorent; Yannick Vande Weygaerde; Gijs Van Pottelbergh; Lode Godderis; Marc Van Ranst; Emmanuel André; Elizaveta Padalko; Katrien Lagrou; Stien Vandendriessche; Pieter Vermeersch
Journal:  Diagn Microbiol Infect Dis       Date:  2022-02-12       Impact factor: 2.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.